Business
Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 127 million, which is an increase of approximately 31 percent compared to the royalty obtained by BioArctic for the fourth quarter 2024.
About this update from Eisai Co., Ltd.
[{"type":"text","content":"STOCKHOLM, Feb. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 127 million, which is an increase of approximately 31 percent compared to the royalty obtained by BioArctic for the fourth quarter 2024. ","length":522,"tagName":"p"},{"type":"text","content":"The strong appreciation of the Swedish krona during 2025 has had a significant impact on the growth of royalty received in the fourth quarter. With constant exchange rates, the increase in recorded royalty in SEK would have been approximately 50 percent.","length":254,"tagName":"p"},{"type":"text","content":"Eisai's results for their third quarter FY2025 (Oct-Dec 2025) will be published on February 9, 2026.","length":104,"tagName":"p"},{"type":"text","content":"BioArctic's report for the full year 2025 will be published on February 18, 2026, at 08:00 CET.","length":99,"tagName":"p"},{"type":"text","content":"This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on February 6, 2026, at 12:00 CET.","length":263,"tagName":"p"},{"type":"text","content":"For further information, please contact: Oskar Bosson, VP Communications and Investor RelationsE-mail: [email protected] Telephone: +46 704 107 180Jenny Ljunggren, External Communications and Investor Relations ManagerE-mail: [email protected]: +46 76 013 86 08","length":302,"tagName":"p"},{"type":"text","content":"About Leqembi® (lecanemab)","length":31,"tagName":"p"},{"type":"text","content":"Leqembi is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).","length":243,"tagName":"p"},{"type":"text","content":"Leqembi is approved in 53 countries and is under regulatory review in 6 countries. Following the initial phase ...